Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
904 participants
OBSERVATIONAL
2023-05-09
2025-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Women's Improvement of Sexual Health (WISH) Demonstration Project
NCT03045809
Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males
NCT03218839
Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity
NCT02445989
Trial to Assess Acceptability and Safety of Two Placebo Intravaginal Rings
NCT06163274
A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa
NCT01337583
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The two main study components include the following:
1. Prospective, observational cohort of eligible individuals interested in initiating PrEP or continuing PrEP with screening for entry at time of HIV testing and followed throughout the study period (up to 18 months). Data collection will involve quantitative methods and for a subset of participants, data will also be collected using qualitative means, namely in-depth interviews, and focus group discussions.
2. Mixed methods process evaluation that will document implementation of the enhanced service delivery package, assess ongoing perceptions of service delivery (i.e., acceptability and feasibility, barriers and facilitators) among providers and end users, and document other important implementation considerations including the integration of PrEP and family planning.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Agency for International Development (USAID)
FED
FHI 360
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anita Hettema, MPH
Role: PRINCIPAL_INVESTIGATOR
FHI 360
Sindy Matse, MPH
Role: PRINCIPAL_INVESTIGATOR
Ministry of Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dvokolwako Health Centre
Dvokolwako, , Eswatini
Manzini KP Community Centre
Manzini, , Eswatini
Matsapha Mobile Clinic
Matsapha, , Eswatini
Mbabane Key Population (KP) Community Centre
Mbabane, , Eswatini
Mbabane Public Health Unit
Mbabane, , Eswatini
Motshane Clinic
Mbabane, , Eswatini
Siphofaneni Inkhundla (DREAMS Outreach)
Siphofaneni, , Eswatini
New Haven Clinic
Velebantfu, , Eswatini
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FHI 360
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.